Literature DB >> 20453419

Effect of urinary trypsin inhibitor on preterm labor with high granulocyte elastase concentration in cervical secretions.

Masako Hayashi1, Atsuko Oya, Hidehiko Miyake, Akihito Nakai, Toshiyuki Takeshita.   

Abstract

AIMS: To explore whether intravaginal treatment with urinary trypsin inhibitor (UTI) prevents preterm delivery in patients in preterm labor with increased levels of granulocyte elastase in cervical secretions.
METHODS: The subjects were patients in preterm labor with increased levels of granulocyte elastase in cervical secretions from 16 to 33 weeks gestation. Maternal and neonatal outcomes were compared between patients receiving UTI treatment (UTI group; n=33) and those not receiving UTI treatment (control group; n=40).
RESULTS: In patients receiving UTI, the mean gestational age at delivery was greater than that in the control group (37.8 vs. 35.6 weeks, p=0.003), and the rates of premature delivery before 34 and 37 weeks gestation were lower (3% vs. 20%, p=0.028; and 18% vs. 47%, p=0.008, respectively). The percentage of neonates weighing more than 2,500 g was significantly higher in the UTI group, with no neonates weighing less than 1,500 g. The neonatal hospitalization rate was lower in the UTI group (9% vs. 42%, p=0.001).
CONCLUSION: In patients in preterm labor with a high elastase concentration in cervical secretions, treatment with UTI reduced the risk of preterm delivery and improved neonatal outcomes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20453419     DOI: 10.1272/jnms.77.80

Source DB:  PubMed          Journal:  J Nippon Med Sch        ISSN: 1345-4676            Impact factor:   0.920


  1 in total

1.  Re-evaluation of Urinary Trypsin Inhibitor on Pregnancy Course in Patients with Threatened Preterm Delivery: A Single-Center Retrospective Study.

Authors:  Hiroaki Komatsu; Fuminori Taniguchi; Takashi Harada; Takaya Nakaso; Noriko Nishimura; Satoru Tsukihara; Masako Sarugami; Tasuku Harada; Yasunobu Kanamori
Journal:  Yonago Acta Med       Date:  2019-06-20       Impact factor: 1.641

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.